Cobra Biomanufacturing Plc, the international manufacturer of biopharmaceuticals, has extended its manufacturing agreement and intends to form a joint venture with ViroMed Co. Ltd (South Korea), a specialist in the development of DNA and protein-based therapeutics.

The extended collaboration includes a long term research, development and technical consultancy agreement for all ViroMed products. The agreement will provide ViroMed with guaranteed process development and manufacturing resources.

Additionally, the companies have signed a memorandum of understanding to explore the potential of establishing a joint venture commercial scale biomanufacturing company that would enable the JV Company to manufacture ViroMed products for commercial supply, at the joint venture's new facilities.

These agreements extend the manufacturing collaboration announced in June 2008, under which Cobrabio will manufacture ViroMed's plasmid DNA therapeutic, VM206RY, for the treatment of tumours expressing Her2/neu.